



Valitor, Inc.



Contact:
Wesley M. Jackson

Location:
Berkeley, CA

Email:
wjackson@valitorbio.com

Tel:
510.969.9246

Website:
<http://www.valitorbio.com>



Company Profile

Industry Sector: Biotechnology

Company Overview: Valitor’s mission is to improve the efficacy, safety, and convenience of protein-based drugs. Our core technology platform was developed at UC Berkeley, and we have obtained an exclusive Option Agreement to license this technology in all fields of use. Valitor was founded in October 2010, and is currently operating in Berkeley, California. We have three full-time employees

Target Market(s): We are developing multiple products with applications in dermatology, ophthalmology, oncology and orthopedics.



Key Value Drivers

Technology*: Our core technology platform is based on the production of soluble, nanoscale clusters of proteins conjugated to single-chain biopolymers. By tuning the size of the conjugate and number of protein copies on each biopolymer backbone, we can engineer their potency, stability, and duration of their bioactivity.

Competitive Advantage: The ability to independently control the pharmacodynamic and pharmacokinetic properties of our drug products differentiates our technology from other methods of modifying protein-based drugs. We can generate highly potent drugs that provide sustained therapeutic activity in the target tissues.

Plan & Strategy: We have initiated a pipeline of protein therapies that can demonstrate the clinical advantages of multivalent conjugation to our potential industry partners.




Management

Leadership: Wesley M. Jackson (CSO and Acting CEO)

Scientific Advisory Board: Our scientific advisory board includes Kevin E. Healy and David S. Schaffer, who co-developed the multivalent conjugation technology in their laboratories at UC Berkeley. We have also recruited clinicians with expertise in our targeted disease areas to facilitate the development of our drug products.



Product Pipeline



We are currently developing IND candidates for our most advanced products. We are also in the process of *in vivo* validation for follow-on products in dermatology, oncology and orthopedics.